The Authors review immunotherapy attempts to treat metastatic breast cancer. They include a) the addition of cytokines to endocrine therapy, b) monoclonal antibodies associated to chemotherapy and c) vaccination.
Two University of Colorado Cancer Center studies presented at ENDO 2018 use new models to identify genetic targets and test promising treatments in adrenal cancer. One patient was treated with the immunotherapy pembrolizumab and now more than a year after starting treatment remains on the drug with 77 percent tumor reduction and no new metastases.
A team of physicists has developed a method to generate and self-organize liquids into well-defined patterns, a breakthrough that offers potential new pathways for the development of more sophisticated pharmaceuticals and other consumer products.
A new, biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer's disease (AD)-related amyloid-β peptide (Aβ) under near-infrared (NIR) light irradiation is developed. The catalyst was able to oxygenate Aβ embedded under the skin of a living mouse, and diminished intact Aβ level in AD-model mouse brain. The new catalyst is potentially applicable for the treatment of peripheral amyloid diseases and AD.
Treatments for the anti-NMDA receptor encephalitis usually include steroids, intravenous immunoglobulin, plasma exchange, plasmapheresis, rituximab, cyclophosphamide and tumor resection. The researchers aimed to compare the efficacy of the treatments including intravenous immunoglobulin, plasma exchange, plasmapheresis, rituximab or cyclophosphamide for male anti-NMDA receptor encephalitis patients without tumor and to discuss potential biomarkers for this disease.
One in 10 people in America is fighting a rare disease, or a disorder that affects fewer than 200,000 Americans. Researchers have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.
Researchers at The Scripps Research Institute (TSRI) have designed a new molecule-building method that uses sulfones as partners for cross-coupling reactions, or the joining of two distinct chemical entities in a programmed fashion aided by a catalyst.
Researchers say they can now produce a vast library of unique cyclic compounds, some with the capacity to interrupt specific protein-protein interactions that play a role in disease. The new compounds have cyclic structures that give them stability and enhance their ability to bind to their targets.
A University of Colorado Cancer Center study published March 12 in the journal Developmental Cell suggests inhibiting molecule FOXO3a could increase effectiveness of autophagy-inhibitors, which have shown promise but little success in clinical practice.
Heart disease patients have lower levels of an important family of protective molecules in their blood in the morning, which could be increasing risk of blood clots and heart attacks at those times, says early research by Queen Mary University of London.